Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

77 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Radue EW, et al. Among authors: sandrock aw. J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. J Neurol Sci. 2010. PMID: 20236661 Clinical Trial.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Rudick RA, et al. Among authors: sandrock aw. N Engl J Med. 2006 Mar 2;354(9):911-23. doi: 10.1056/NEJMoa044396. N Engl J Med. 2006. PMID: 16510745 Clinical Trial.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Polman CH, et al. Among authors: sandrock aw. N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397. N Engl J Med. 2006. PMID: 16510744 Clinical Trial.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. Bloomgren G, et al. Among authors: sandrock a. N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829. N Engl J Med. 2012. PMID: 22591293
Infusion-related hypersensitivity reactions during natalizumab treatment.
Phillips JT, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Polman CH, Lublin FD, Giovannoni G, Wajgt A, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Phillips JT, et al. Among authors: sandrock aw. Neurology. 2006 Nov 14;67(9):1717-8. doi: 10.1212/01.wnl.0000242629.66372.33. Neurology. 2006. PMID: 17101921 Clinical Trial. No abstract available.
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Miller DH, et al. Among authors: sandrock aw. Neurology. 2007 Apr 24;68(17):1390-401. doi: 10.1212/01.wnl.0000260064.77700.fd. Neurology. 2007. PMID: 17452584 Clinical Trial.
77 results